| 金 一,姜大庆,马 特.新辅助内分泌治疗后腋窝转移淋巴结中Ki-67蛋白表达对绝经后乳腺癌预后的影响[J].肿瘤学杂志,2016,22(12):1042-1047. |
| 新辅助内分泌治疗后腋窝转移淋巴结中Ki-67蛋白表达对绝经后乳腺癌预后的影响 |
| Association Between Expression of Ki-67 in Axillary Lymph Nodes and Prognosis of Postmenopausal Breast Cancer Patients After Neoadjuvant Endocrine Therapy |
| 投稿时间：2016-04-19 |
| DOI：10.11735/j.issn.1671-170X.2016.12.B012 |
|
 |
| 中文关键词: 新辅助内分泌治疗 腋窝淋巴结 Ki-67 预后 乳腺肿瘤 |
| 英文关键词:neoadjuvant endocrine therapy axillary lymph nodes Ki-67 prognosis breast neoplasms |
| 基金项目:国家自然科学基金项目（81572831） |
|
| 摘要点击次数: 1850 |
| 全文下载次数: 657 |
| 中文摘要: |
| 摘 要：［目的］ 探讨乳腺癌新辅助内分泌治疗后腋窝转移淋巴结中Ki-67蛋白的表达和患者预后的关系。［方法］ 回顾性分析108例新辅助内分泌治疗腋窝转移淋巴结乳腺癌患者的临床和病理资料。结果 108例患者中，术后淋巴结Ki-67蛋白＞10%者71例，Ki-67≤10%者37例。全组中位随访40个月，其中Ki-67≤10%组和Ki-67＞10%组无病生存率分别为83.8%，54.9%，差异有统计学意义（P=0.004）；总生存率分别为91.9%和71.8%，差异有统计学意义（P=0.019）。COX多因素分析的结果显示，术后腋窝淋巴结Ki-67蛋白表达的状态是影响患者无病生存和总生存的主要因素（RR=0.300，95%CI为0.125~0.718，P=0.007；RR=0.260，95%CI为0.077~0.876，P=0.030）。［结论］ 新辅助内分泌治疗后腋窝淋巴结Ki-67蛋白表达的高低是预测乳腺癌患者预后的有效指标。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the association between expression of Ki-67 in axillary lymph nodes and prognosis in postmenopausal breast cancer patients after neoadjuvant endocrine therapy. ［Methods］ The clinical and pathological data of 108 postmenopausal breasts cancer patients who underwent neoadjuvant endocrine therapy were analyzed retrospectively. ［Results］ The median follow up time was 40 months. Among 108 patients the expression of Ki-67 in axillary lymph nodes was ＞10% in 71 cases and expression of Ki-67 was ≤10% in 37 cases. The disease free survival（DFS） in the two groups was 54.9% and 83.8%（P=0.004），the overall survival（OS） was 71.8% and 91.9%（P=0.019），respectively. The multivariate analysis indicated that the expression of Ki-67 in axillary lymph nodes was an independent prognostic factor for DFS and OS (RR=0.300，95%CI：0.125~0.718，P=0.007；RR=0.260，95%CI：0.077~0.876，P=0.030）.［Conclusion］ The expression of Ki-67 in axillary lymph nodes is an effective indicator for predicting the prognosis of postmenopausal breast cancer patients after neoadjuvant endocrine therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |